Core Viewpoint - Ying Tai Medical (01501) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Group 1: Company Actions - The company has applied to convert a total of 71.7866 million domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - The conversion and listing of these domestic shares as H-shares will occur once all necessary approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained [1] - According to the company's articles of association, there is no requirement to hold a shareholders' meeting to approve the conversion and listing [1]

Core Viewpoint - Ying Tai Medical (01501) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Summary by Relevant Sections - **H-share Conversion** - The company has applied to convert a total of 71.7866 million domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - **Regulatory Approval** - The conversion of domestic shares into H-shares will occur once all necessary filings and approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained, ensuring compliance with applicable laws and regulations [1] - **Shareholder Meeting Requirement** - According to the company's articles of association, there is no need to convene a shareholder meeting to approve the conversion and listing of the shares [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 內幕消息 本公司建議實施 H股全流通 本公告 由上海瑛 泰醫療器械 股份有限 公司（「本 公司」）根據香港 聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09 (2)條及香港法例第 571章證券及期貨 條例第XIVA部 項下的內幕 消息條文（ 定義 見上市規則 ）作 出。 茲提述(i)中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈 並於2023年8月10日修訂的《H股公司境內 未上市股份申 請「 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股 ...

Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]

Core Viewpoint - Kintor Pharmaceutical-B (02216) has seen a significant increase in stock price, rising over 9% during trading, with a current price of 3.25 HKD and a trading volume of 11.79 million HKD. The company announced plans to issue a total of 105 million subscription shares at a price of 3.11 HKD per share, representing a premium of approximately 1.3% over the previous closing price. The net proceeds of approximately 327 million HKD will be used for potential acquisitions in the medical device industry, as the company seeks to expand its product portfolio [1][1][1]. Group 1 - Kintor Pharmaceutical plans to issue 105 million subscription shares at 3.11 HKD each, raising approximately 327 million HKD for acquisitions [1][1][1]. - The stock price of Kintor Pharmaceutical has increased by over 9% during trading, reflecting positive market sentiment [1][1][1]. - The company is currently in discussions with various parties to identify potential acquisition targets in the medical device sector [1][1][1]. Group 2 - Ying Tai Medical (01501) intends to invest approximately 283 million HKD to subscribe for about 91.09 million shares of Kintor Pharmaceutical [1][1][1]. - The subscription is expected to enhance Kintor Pharmaceutical's strategic positioning in the non-vascular interventional field, where it already has a rich product line [1][1][1].

Core Viewpoint - Ying Tai Medical (01501.HK) has entered into a subscription agreement with Kunbo Medical to acquire a total of 91.09 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.30% over the closing price on the Hong Kong Stock Exchange [1] Group 1 - The total consideration for the subscription is HKD 283 million, excluding transaction costs, and is subject to the terms and conditions of the subscription agreement [1] - Upon completion, the company will hold approximately 17.24% of Kunbo Medical's issued shares, or about 14.38% of the expanded issued shares post-transaction [1] - Kunbo Medical is an innovative enterprise in the field of interventional pulmonology, focusing on the development of minimally invasive diagnostic and therapeutic products for lung diseases, particularly COPD and lung cancer [1] Group 2 - The subscription is expected to further expand the company's strategic layout in the non-vascular interventional field, given Kunbo Medical's rich product line in this area [2] - The board of directors, including independent non-executive directors, believes that the terms of the subscription agreement are fair and reasonable, established on normal commercial terms, and in the overall interest of the company and its shareholders [2]

Core Viewpoint - Ying Tai Medical (01501) has entered into a subscription agreement with Kunbo Medical, agreeing to issue a total of 91,093,613 subscription shares at a price of HKD 3.11 per share, totaling HKD 283,301,136.43, subject to the terms and conditions of the agreement [1] Group 1 - The subscription will result in Ying Tai Medical holding approximately 17.24% of Kunbo Medical's issued shares as of the announcement date, and approximately 14.38% of the expanded issued shares post-transaction [1] - The financial performance of Kunbo Medical will not be consolidated into Ying Tai Medical's accounts [1] - The subscription is aimed at expanding Ying Tai Medical's strategic layout in the non-vascular interventional field, leveraging Kunbo Medical's rich product line in this area [1]

Core Viewpoint - Ying Tai Medical (01501) has entered into a subscription agreement with Kunbo Medical to issue a total of 91,093,613 subscription shares at a price of HKD 3.11 per share, totaling HKD 283,301,136.43, subject to the terms and conditions of the agreement [1] Group 1: Subscription Agreement Details - The subscription price is set at HKD 3.11 per share, with a total consideration of HKD 283,301,136.43, excluding transaction costs [1] - Upon completion, Ying Tai Medical will hold 91,093,613 shares of Kunbo Medical, representing approximately 17.24% of Kunbo Medical's issued shares as of the announcement date, or about 17.30% if treasury shares are excluded [1] - The issuance will increase Kunbo Medical's total issued shares, resulting in Ying Tai Medical holding approximately 14.38% of the expanded issued shares, or about 14.42% if treasury shares are excluded [1] Group 2: Strategic Implications - The subscription is expected to enhance Ying Tai Medical's strategic positioning in the non-vascular interventional field, leveraging Kunbo Medical's extensive product line in this area [1]

（ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 須予披露交易 認購堃博醫療控股有限公司新股份 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券之邀請或要約。 Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 上市規則的涵義 於完成後，本公司將合共持有91,093,613股堃博醫療股份，分別相當於堃博 醫療於本公告日期已發行堃博醫療股份約17.24%（ 若不計算庫存股，則為約 17.30% ）及 因 本 次 發 行 認 購 股 份 而 擴 大 之 堃 博 醫 療 已 發 行 堃 博 醫 療 股 份 約 14.38%（ 若不計算庫存股，則為 ...